000133435 001__ 133435
000133435 005__ 20240416133904.0
000133435 0247_ $$2doi$$a10.4235/agmr.23.0137
000133435 0248_ $$2sideral$$a138108
000133435 037__ $$aART-2024-138108
000133435 041__ $$aeng
000133435 100__ $$aMatovelle, Priscila$$uUniversidad de Zaragoza
000133435 245__ $$aPolypharmacy in older patients: A three-year longitudinal analysis in primary care settings of Aragón, Spain
000133435 260__ $$c2024
000133435 5060_ $$aAccess copy available to the general public$$fUnrestricted
000133435 5203_ $$aBackground: Challenges of polypharmacy and the impact of coronavirus disease 2019 (COVID-19) pandemic in older patients require further investigation. This retrospective study analyzed the progression of polypharmacy and anticholinergic burden in older patients in a primary care setting before, during, and after the COVID-19 pandemic. Methods: This 3-year cross-sectional study (2019, 2020, and 2021) comprised a dynamic cohort of individuals aged ≥75 years, who attended the Arrabal Primary Care Center in Zaragoza, Spain. Older patients with polypharmacy (≥5 medications) were identified according to their electronic health records. We collected demographic and clinical data, including medication prescriptions, diagnoses, and anticholinergic risks, and performed descriptive and statistical analyses. Results: This study included a total of 1,928 patients with a mean age of 83.52±0.30 years. Over the 3-year study period, the mean number of medications prescribed increased, from 9.4 in 2019 to 10.4 in 2021. The prevalence of excessive polypharmacy (≥10 medications) increased from 39% in 2019 to 45% in 2021. The most commonly prescribed drugs were anilides, proton pump inhibitors, benzodiazepine derivatives, and platelet aggregation inhibitors. Women had a higher prevalence of illnesses and anticholinergic drug prescriptions than men. Conclusion: The results of this study highlighted an upward trend in polypharmacy and excessive polypharmacy among older patients in primary care settings. Future research should focus on optimizing medication management and deprescribing strategies and minimizing the adverse effects of polypharmacy in this population.
000133435 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B21-23R-GAIAP
000133435 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000133435 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000133435 700__ $$0(orcid)0000-0001-6565-9699$$aOliván-Blázquez, Bárbara$$uUniversidad de Zaragoza
000133435 700__ $$aFraile-Peñaranda, Irene
000133435 700__ $$0(orcid)0000-0002-8807-8958$$aTurón-Lanuza, Alberto$$uUniversidad de Zaragoza
000133435 700__ $$aGallego-Royo, Alba
000133435 700__ $$aCasado-Vicente, Verónica
000133435 700__ $$0(orcid)0000-0002-5494-6550$$aMagallón-Botaya, Rosa$$uUniversidad de Zaragoza
000133435 7102_ $$14009$$2740$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicología Social
000133435 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000133435 7102_ $$14014$$2623$$aUniversidad de Zaragoza$$bDpto. Economía Aplicada$$cÁrea Métodos Cuant.Econ.Empres
000133435 773__ $$g28, 1 (2024), 36-45$$tAnnals of Geriatric Medicine and Research$$x2508-4798
000133435 8564_ $$s597120$$uhttps://zaguan.unizar.es/record/133435/files/texto_completo.pdf$$yVersión publicada
000133435 8564_ $$s2664433$$uhttps://zaguan.unizar.es/record/133435/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000133435 909CO $$ooai:zaguan.unizar.es:133435$$particulos$$pdriver
000133435 951__ $$a2024-04-16-13:15:23
000133435 980__ $$aARTICLE